The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine

  • Suhua Huang School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangdong, Guangzhou, P.R. China 510006.
  • Mingxia Lin School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangdong, Guangzhou, P.R. China 510006.
  • Xiaowei Pan School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangdong, Guangzhou, P.R. China 510006.
  • Qiwen Tan Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangdong, Guangzhou, P.R. China 510006.
  • Kai-Leng Tan Institute of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangdong, Guangzhou, P.R. China 510006. https://orcid.org/0000-0003-2597-5632
Keywords: MLC901, cerebral ischemia, traditional Chinese medicine

Abstract

Stroke, also known as cerebral ischemia, is a common neurological disease. The therapeutic potential of MLC901 (NeuroAiD II™) has been reported in clinical trials on traumatic brain injury as well as in animal and cell models. MLC901 reduced the infarction size, ischemia-induced neurological deficits and pro-inflammatory infiltration of phagocyte. It also inhibited the ischemia-induced expression of pro-inflammatory mediators and Prx6, TLR4 signalling, and phosphorylation of NFκB. We found that the beneficial effects of MLC901 are in coherent with studies performed on the individual active ingredient. MLC901 may develop its efficacy through a synergistic effect via nine herbal extracts. MLC901 is a multifaceted traditional Chinese medicine. A cocktail of herbs provides a broader spectrum of targets. This may surpass single-target drug treatment in terms of side effect and therapeutic efficacy. MLC901 leads to various potential research directions on the development or improvement of a feasible, effective and promising herbal formulation for treating stroke patients.

References

Arvidsson A, Kokaia Z, Lindvall O. N-methyl-d-aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke. European Journal of Neuroscience. 2001; 14(1):10-18. https://doi.org/10.1046/j.0953-816x.2001.01611.x

Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-Like Receptor 4 Is Involved in Brain Damage and Inflammation After Experimental Stroke. Circulation. 2007; 115(12):1599-1608. https://doi.org/10.1161/CIRCULATIONAHA.106.603431

Chen CLH, Young SHY, Gan HH, Singh R, Lao AY, Baroque AC, et al. Chinese Medicine Neuroaid Efficacy on Stroke Recovery. Stroke. 2013; 44(8):2093-2100. https://doi.org/doi:10.1161/STROKEAHA.113.002055

Cheng CY, Ho TY, Lee EJ, Su SY, Tang NY, Hsieh CL. Ferulic Acid Reduces Cerebral Infarct Through Its Antioxidative and Anti-Inflammatory Effects Following Transient Focal Cerebral Ischemia in Rats. American Journal of Chinese Medicine. 2008; 36(06):1105-1119. https://doi.org/10.1142/S0192415X08006570

Cheng NT, Kim AS. Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset. The Neurohospitalist. 2015; 5(3):101-109. https://doi.org/10.1177/1941874415583116

Chowbay B, Sheu FS. Tanshinone ⅡB,a primary active constituent from Salvia miltiorrhza,exhibits neuro-protective activity in experimentally stroked rats. Neuroscience Letters. 2007; 417(3):261-265. https://doi.org/10.1016/j.neulet.2007.02.079

Christopher C, Venketasubramanian N, Gan RN, Caroline L, David P, Chan BPL, et al. Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery. Stroke. 2009; 40(3):859-863. https://doi.org/10.1161/STROKEAHA.108.531616

D W Choi a, Rothman SM. The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death. Annual Review of Neuroscience. 1990; 13(1):171-182. https://doi.org/10.1146/annurev.ne.13.030190.001131

Diener HC, Ringelstein EB, Kummer R, Von, Langohr HD, Bewermeyer H, ., Landgraf H, ., et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke; a journal of cerebral circulation. 2001; 32(1):22

Diener HC, Ringelstein EB, von Kummer R, Langohr HD, Bewermeyer H, Landgraf H, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke. 2001; 32(1):22-29. https://doi.org/10.1161/01.str.32.1.22

Gasparotto J, Somensi N, Bortolin RC, Girardi CS, Kunzler A, Rabelo TK, et al. Preventive supplementation with fresh and preserved peach attenuates CCl4-induced oxidative stress, inflammation and tissue damage. The Journal of nutritional biochemistry. 2014; 25(12):1282-1295. https://doi.org/10.1016/j.jnutbio.2014.07.004

Gu J, Chen J, Yang N, Hou X, Wang J, Tan X, et al. Combination of Ligusticum chuanxiong and Radix Paeoniae ameliorate focal cerebral ischemic in MCAO rats via endoplasmic reticulum stress-dependent apoptotic signaling pathway. Journal of Ethnopharmacology. 2016; 187:313-324. https://doi.org/10.1016/j.jep.2016.04.024

Gu J, Su S, Guo J, Zhu Y, Zhao M, Duan JA. Anti-inflammatory and anti-apoptotic effects of the combination of Ligusticum chuanxiong and Radix Paeoniae against focal cerebral ischaemia via TLR4/MyD88/MAPK/NF-kappaB signalling pathway in MCAO rats. The Journal of pharmacy and pharmacology. 2018; 70(2):268-277. https://doi.org/10.1111/jphp.12841

Hai-Bo Z, Ling Z, Zheng-Hua W, Jing-Wei T, Feng-Hua F, Ke L, et al. Therapeutic effects of hydroxysafflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms. Journal of Asian Natural Products Research. 2005; 7(4):607-613. https://doi.org/10.1080/10286020310001625120

Hankey GJ, Blacker DJ. Is it a stroke? BMJ. 2015; 350(jan15 1):h56-h56. https://doi.org/10.1136/bmj.h56

Hankey GJ. Stroke. The Lancet. 2017; 389(10069):641-654. https://doi.org/10.1016/S0140-6736(16)30962-X

Harari OA, Liao JK. NF-κB and innate immunity in ischemic stroke. Annals of the New York Academy of Sciences. 2010; 1207:32-40. https://doi.org/10.1111/j.1749-6632.2010.05735.x

He YL, Zhe D, Dong LY: Protective effects of total paeny glycoside against focal cerebral ischemia/reperfusion injury in rats. 2006; vol. 10.

Heurteaux C, Gandin C, Borsotto M, Widmann C, Brau F, Lhuillier M, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58(7):987-1001. https://doi.org/10.1016/j.neuropharm.2010.01.001

Heurteaux C, Gandin CM, Widmann C, Brau F, Lhuillier M, Onteniente B, et al. Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. Neuropharmacology. 2010; 58(7):987-1001. https://doi.org/10.1016/j.neuropharm.2010.01.001

Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nature Medicine. 2011; 17:796. https://doi.org/10.1038/nm.2399

Ikonomidou C, Stefovska V, Turski L. Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(23):12885-12890. https://doi.org/10.1073/pnas.220412197

Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurology. 2002; 1(6):383-386. https://doi.org/10.1016/S1474-4422(02)00164-3

Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia Biochimica Et Biophysica Acta. 2016; 1862(5):915-925. https://doi.org/10.1016/j.bbadis.2016.01.015

Kao TK, Ou YC, Kuo JS, Chen WY, Liao SL, Wu CW, et al. Neuroprotection by tetramethylpyrazine against ischemic brain injury in rats. Neurochemistry International. 2006; 48(3):166-176. https://doi.org/10.1016/j.neuint.2005.10.008

Kuang X, Yao Y, Du JR, Liu YX, Wang CY, Qian ZM. Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice. Brain Research. 2006; 1102(1):145-153. https://doi.org/10.1016/j.brainres.2006.04.110

Leslie J, Nigel S, Debra R. Reducing the risk of adverse thrombotic events - The role of aspirin and clopidogrel. Australian Family Physician. 2008; 37(9):725-726

Li P, Gan Y, Sun BL, Zhang F, Lu B, Gao Y, et al. Adoptive regulatory T-cell therapy protects against cerebral ischemia. Annals of neurology. 2013; 74(3):458-471. https://doi.org/10.1002/ana.23815

Li P, Mao L, Zhou G, Leak RK, Sun BL, Chen J, et al. Adoptive regulatory T-cell therapy preserves systemic immune homeostasis after cerebral ischemia. Stroke. 2013; 44(12):3509-3515. https://doi.org/10.1161/strokeaha.113.002637

Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS, Huang RX. Enhanced angiogenesis with dl -3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Research. 2009; 1289(1289):69-78. https://doi.org/10.1016/j.brainres.2009.06.018

Liao SL, Kao TK, Chen WY, Lin YS, Chen SY, Raung SL, et al. Tetramethylpyrazine reduces ischemic brain injury in rats. Neuroscience Letters. 2004; 372(1):40-45. https://doi.org/10.1016/j.neulet.2004.09.013

Liu L, Fang YQ, Xue ZF, He YP, Fang RM, Li L. Beta-asarone attenuates ischemia–reperfusion-induced autophagy in rat brains via modulating JNK, p-JNK, Bcl-2 and Beclin 1. European Journal of Pharmacology. 2012; 680(1-3):34-40. https://doi.org/10.1016/j.ejphar.2012.01.016

Marsh B, Stevens SL, Packard AEB, Gopalan B, Hunter B, Leung PY, et al. Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2009; 29(31):9839-9849. https://doi.org/10.1523/JNEUROSCI.2496-09.2009

Mijajlović MD, Pavlović A, Brainin M, Heiss W-D, Quinn TJ, Ihle-Hansen HB, et al. Post-stroke dementia – a comprehensive review. Bmc Medicine. 2017; 15(1):11. https://doi.org/10.1186/s12916-017-0779-7

Navarro JC, Chen CL, Lee CF, Gan HH, Lao AY, Baroque AC, et al. Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies. International Journal of Stroke. 2017; 12(3):285-291. https://doi.org/10.1177/1747493016676615

Richard M, Carine A, Olivier T, Brigitte LM, Gilles D, Ulrich D, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurology. 2011; 10(5):471-480. https://doi.org/10.1016/S1474-4422(11)70066-7

Sheng-Ying Y, Wen-Yuan G. Hydroxysafflor yellow A protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats. Archives of Pharmacal Research. 2008; 31(8):1010-1015. https://doi.org/10.1007/s12272-001-1261-y

Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, et al. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nature Medicine. 2012; 18(6):911. https://doi.org/10.1038/nm.2749

Sun L, Yang L, Xu YW, Liang H, Han J, Zhao RJ, et al. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: Inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood–brain barrier disruption. Brain Research. 2012; 1473(6):227-235. https://doi.org/10.1016/j.brainres.2012.07.047

Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL. MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial. European journal of neurology. 2018; 25(8):1055-e1082. https://doi.org/10.1111/ene.13653

Wang HL, Zhou QH, Xu MB, Zhou XL, Zheng GQ. Astragaloside IV for Experimental Focal Cerebral Ischemia: Preclinical Evidence and Possible Mechanisms. Oxidative Medicine & Cellular Longevity. 2017; 2017(1):8424326. https://doi.org/10.1155/2017/8424326

Wang Y, Chen G, Yu X, Li Y, Zhang L, He Z, et al. Salvianolic Acid B Ameliorates Cerebral Ischemia/Reperfusion Injury Through Inhibiting TLR4/MyD88 Signaling Pathway. Inflammation. 2016; 39(4):1-11. https://doi.org/10.1007/s10753-016-0384-5

Widmann C, Gandin C, Petit-Paitel A, Lazdunski M, Heurteaux C. The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. Scientific Reports. 2018; 8(1):18062. https://doi.org/10.1038/s41598-018-36138-0

Widmann C, Gandin C, Petit-Paitel A, Lazdunski M, Heurteaux C. The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. Sci Rep. 2018; 8(1):18062. https://doi.org/10.1038/s41598-018-36138-0

Xue B, Huang J, Ma B, Yang B, Chang D, Liu J. Astragaloside IV Protects Primary Cerebral Cortical Neurons from Oxygen and Glucose Deprivation/Reoxygenation by Activating the PKA/CREB Pathway. Neuroscience. 2019; 404:326-337. https://doi.org/10.1016/j.neuroscience.2019.01.040

Yang YX, Chen YT, Zhou XJ, Hong CL, Li CY, Guo JY. Beta-asarone, a major component of Acorus tatarinowii Schott, attenuates focal cerebral ischemia induced by middle cerebral artery occlusion in rats. Bmc Complementary & Alternative Medicine. 2013; 13(1):236

Yi C, George H, Seu-Hwa C, Yi-Cheng C, Jiing-Han L, Kuang-Hung L, et al. Tetramethylpyrazine suppresses HIF-1alpha, TNF-alpha, and activated caspase-3 expression in middle cerebral artery occlusion-induced brain ischemia in rats. Acta Pharmacologica Sinica. 2007; 28(3):327-333. https://doi.org/10.1111/j.1745-7254.2007.00514.x

Yi J-H, Park S-W, Kapadia R, Vemuganti R. Role of transcription factors in mediating post-ischemic cerebral inflammation and brain damage. Neurochemistry international. 2007; 50(7-8):1014-1027. https://doi.org/10.1016/j.neuint.2007.04.019

You ZQ, Min L, Yan LZ, Zhen WZ, Xiao YW, Jin PL, et al. Astragaloside IV attenuates cerebral ischemia–reperfusion-induced increase in permeability of the blood-brain barrier in rats. European Journal of Pharmacology. 2009; 606(1):137-141. https://doi.org/10.1016/j.ejphar.2009.01.022

Zhang H, Xia Y, Ye Q, Yu F, Zhu W, Li P, et al. In Vivo Expansion of Regulatory T Cells with IL-2/IL-2 Antibody Complex Protects against Transient Ischemic Stroke. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2018; 38(47):10168-10179. https://doi.org/10.1523/jneurosci.3411-17.2018

Published
2019-05-22
How to Cite
Huang, S., Lin, M., Pan, X., Tan, Q. and Tan, K.-L. (2019) “The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine”, Neuroscience Research Notes, 2(2), pp. 18-24. doi: 10.31117/neuroscirn.v2i2.32.
Section
News and Views